Jude Onyia, Ph.D., is a distinguished scientist and pharmaceutical executive who currently serves as the Chief Scientific Officer at Neurocrine Biosciences Inc. With a robust background in drug discovery and development, Dr. Onyia has been instrumental in steering the company's scientific direction and fostering innovation in treatments for neurological and endocrine-related disorders. Prior to joining Neurocrine Biosciences, he held significant roles at Eli Lilly and Company, where he contributed to the development of several successful drugs, showcasing his expertise in translational research and his ability to bring novel therapies from the lab to the market. At Neurocrine Biosciences, Dr. Onyia's leadership has been pivotal in advancing the company's pipeline of therapeutics targeting complex diseases such as Parkinson's disease, epilepsy, and various psychiatric disorders. His strategic oversight ensures that the company remains at the forefront of scientific innovation, collaborating with leading researchers and leveraging cutting-edge technologies to develop transformative medicines. Under his guidance, Neurocrine Biosciences has continued to expand its research capabilities and has made significant strides in clinical trials, reinforcing its commitment to improving patient outcomes. Dr. Onyia's achievements extend beyond his corporate roles; he is also an active member of the scientific community, contributing to numerous peer-reviewed publications and serving on advisory boards for various scientific organizations. His dedication to advancing the field of neuroscience and his passion for developing new treatments that address unmet medical needs have earned him recognition and respect among his peers. As Chief Scientific Officer, Dr. Onyia continues to drive Neurocrine Biosciences toward its mission of making a meaningful difference in the lives of patients worldwide.